Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.80 |
| ▸ | HMGCR | P04035 | 4/20 | 0.80 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.80 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.80 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.80 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.80 |
| ▸ | PGR | P06401 | 1/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.80 |
| ▸ | RXRA | P19793 | 1/20 | 0.80 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.80 |
| ▸ | CCKAR | P32238 | 1/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.80 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.80 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13987098 | 1.00 | CYP2C9 (0.80) | CYP2C9HMGCRSIRT6NR4A2PDE4D | |
| SCHEMBL4914702 | 0.93 | HMGCR (0.70) | CYP2C9HMGCRSIRT6NR4A2PDE4D | |
| SCHEMBL4914692 | 0.93 | HMGCR (0.70) | CYP2C9HMGCRSIRT6NR4A2PDE4D | |
| SCHEMBL6028729 | 0.93 | HMGCR (0.70) | CYP2C9HMGCRSIRT6NR4A2PDE4D | |
| SCHEMBL4914699 | 0.93 | HMGCR (0.70) | CYP2C9HMGCRSIRT6NR4A2PDE4D | |
| SCHEMBL1503617 | 0.92 | CYP2C9 (0.84) | CYP2C9HMGCRSIRT6NR4A2PDE4D | |
| SCHEMBL14567297 | 0.92 | HMGCR (0.75) | CYP2C9HMGCRSIRT6NR4A2PDE4D | |
| SCHEMBL5685975 | 0.91 | CYP2C9 (0.83) | CYP2C9HMGCRSIRT6NR4A2PDE4D | |
| SCHEMBL557533 | 0.91 | CYP2C9 (0.83) | CYP2C9HMGCRSIRT6NR4A2PDE4D | |
| SCHEMBL5685977 | 0.91 | CYP2C9 (0.83) | CYP2C9HMGCRSIRT6NR4A2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046396-A1 | POLYMORPHIC FORMS OF FLUVASTATIN SODIUM AND PROCESS FOR PREPARING THE SAME | JUBILANT ORGANOSYS LIMITED (IN) | 2011-02-24 | — | — | US | disclosed |
| US-7795451-B2 | Polymorphic forms of fluvastatin sodium and process for preparing the same | JUBILANT ORGANOSYS LIMITED (IN) | 2010-09-14 | — | — | US | disclosed |
| US-20080207919-A1 | Novel Polymorphic Forms Of Fluvastatin Sodium And Process For Preparing The Same | JUBLIANT ORGANOSYS LIMITED (IN) | 2008-08-28 | — | — | US | disclosed |
| WO-2006085338-A2 | NOVEL POLYMORPHIC FORMS OF FLUVASTATIN SODIUM AND PROCESS FOR PREPARING THE SAME | JUBILANT ORGANOSYS LIMITED (IN) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207919-A1 | Novel Polymorphic Forms Of Fluvastatin Sodium And Process For Preparing The Same | CYP4F3, STARD3, CYP2F1 | CYP2C9 50/4885HMGCR 15/4885SIRT6 2630/4885 |
| US-20110046396-A1 | POLYMORPHIC FORMS OF FLUVASTATIN SODIUM AND PROCESS FOR PREPARING THE SAME | CYP4F3, CYP2F1, CYP3A43 | CYP2C9 39/4885HMGCR 19/4885SIRT6 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.